Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01594619 · ClinicalTrials.gov registry record · Phase 1
Study in Healthy Volunteers to Investigate the Effects of Diltiazem on the Pharmacokinetics of Naloxegol
A Phase 1 study of Drug Induced Constipation, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 1
- Development phase
- 44
- Enrollment target
- 1
- Study location
NCT01594619 is a Phase 1 study of Drug Induced Constipation that has completed, run by AstraZeneca. The registered enrollment target is 44 participants. The trial reports 1 study location across 1 state.
The verdict
NCT01594619, a Phase 1 study of Drug Induced Constipation, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 44 participants
- Enrollment target
- 1
- Study location
Study Summary
Study in healthy volunteers to investigate the effects of Diltiazem on the Pharmacokinetics of naloxegol.
Conditions Studied
Interventions
- DRUG Naloxegol
- DRUG Diltiazem XR
Study Locations (1)
Kansas
- Research Site - Overland Park
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 44 participants |
| Start Date | 2012-05 |
| Est. Completion | 2012-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01594619
The ClinicalTrials.gov registry entry for NCT01594619 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 44 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Drug Induced Constipation appearing as the primary indexed condition, and to 2 interventions - of which Naloxegol is the first listed.
NCT01594619 reports 1 study location spanning 1 distinct geographic area - top geographies include Kansas.
Frequently Asked Questions
What is clinical trial NCT01594619 about?
NCT01594619 is a clinical study titled "Study in Healthy Volunteers to Investigate the Effects of Diltiazem on the Pharmacokinetics of Naloxegol". Study in healthy volunteers to investigate the effects of Diltiazem on the Pharmacokinetics of naloxegol.
What is the current status of trial NCT01594619?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 44 participants. The study started on 2012-05. Estimated completion is 2012-08.
What conditions does trial NCT01594619 study?
This clinical trial studies the following conditions: Drug Induced Constipation.
What interventions are being tested in trial NCT01594619?
The interventions under investigation include: Naloxegol (DRUG), Diltiazem XR (DRUG).
Who is sponsoring clinical trial NCT01594619?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01594619 being conducted?
This trial has 1 study location across Kansas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.